August Health vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Assisted living operations and care management platform built for modern senior living communities, replacing paper-based workflows with AI-assisted assessments and digital care planning.
About
August Health is a San Francisco, California-based senior care technology company building a modern cloud-native platform for assisted living and memory care communities. Founded in 2019 and having raised over $14 million from investors including a16z and others, August Health targets the large segment of senior living communities still operating on paper-based or legacy software workflows. The company's platform digitizes resident assessments, care planning, incident reporting, medication management, and family communication in a design-forward interface built for use by care staff on mobile devices.\n\nA key differentiator for August Health is its use of AI to assist care staff in completing state-required assessments and care plans. The platform can generate draft care plan language based on assessment responses, reducing the documentation burden on caregivers while improving consistency and completeness of clinical records. This AI-assisted documentation capability is particularly valuable in assisted living, where staffing challenges and high turnover make efficient documentation workflows critical to operational quality.\n\nAugust Health competes with established vendors like Yardi Senior Living and MatrixCare but targets smaller independent communities and regional groups that find legacy platforms overly complex and expensive for their needs. The company's modern UX, mobile-first design, and AI-assisted features position it as a next-generation alternative in a market where much of the installed base runs on software designed before smartphones existed. As the senior care sector faces mounting staffing pressure, technology that reduces administrative burden on direct care staff is increasingly valued by operators.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.